Histological complete response in a case of advanced gastric cancer treated by chemotherapy with S-1 plus low-dose cisplatin and radiation

Japanese Journal of Clinical Oncology

Volumn 33, Issue 11, 2003, Pages 584-588

  Takahashi, Tsunehiro ^a   Saikawa, Yoshiro ^a   Kubota, Tetsuro ^a   Akiba, Yasutada ^a   Shigematsu, Naoyuki ^a   Yoshida, Masashi ^a   Otani, Yoshihide ^a   Kumai, Koichiro ^a   Hibi, Toshifumi ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Complete response; Gastric cancer; Radiation; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; HEMOGLOBIN; ANTINEOPLASTIC AGENT; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GASTRECTOMY; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; STOMACH CARCINOMA; THROMBOCYTOPENIA; TUMOR VOLUME; DRUG ADMINISTRATION; DRUG COMBINATION; LYMPH NODE; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; REMISSION; STOMACH; STOMACH TUMOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; GASTRECTOMY; GASTROSCOPY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; OXONIC ACID; PYRIDINES; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; STOMACH; STOMACH NEOPLASMS; TEGAFUR;

EID: 1342310686     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg110     Document Type: Article

References (20)

1. Japanese Gastric Cancer Association: Introduction to JGCA gastric cancer treatment guidelines. Tokyo: Kanehara 2001.
2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on Cancer staging, proximal disease and the 'different disease' hypothesis. Cancer 2000;88: 921-32.
3. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys 1990;191:1357-62.
4. Harris BE, Song R, Soong ST, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
5. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
6. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxanic acid of gastrointestinal toxicity of 5-fluorourail without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9.
7. Sugimachi K, Maehara Y. The S-1 gastrointestinal cancer study group: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999; 57:202-10.
8. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluropyrimidine anticancer drug S-1 (1M tegafur-0.4 M, gimestat-1M, otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
9. Koizumi W, Kurihara M, Nakano S, et al. The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
10. Saikawa Y, Akasaka Y, Kanai T, et al. Preoperative combination chemotherapy with S-1 and low-dose cisplatin against highly advanced gastric cancer. Oncology Rep 2003;10:381-6.
11. Iwahashi M, Nakamori M, Tani M, et al. Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: Report of a case report. Oncology 2001;61:16-22.
12. Goldobenko GV, Androsov NS, Byrikhin VI, et al. Efficacy of combined treatment stomach carcinoma with preoperative gammatherapy. Med Radiol (Mosk) 1978;12:26-31.
13. Shchepotin IB, Evans SR, Chorny V, et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg Oncol 1994;3:37-44.
14. Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-year follow-up of a randomized trial. J Surg Oncol 2002;80:72-8.
15. Roth AD, Allal AS, Brundler MA, et al. Neoadjuvant chemoradiotherapy for locally advanced gastric cancer: A phase I - II study. Ann Oncol 2003; 14:110-5.
16. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stermmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
17. Official reference of CTC version 2.0: Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS 1998.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
19. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Trace Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
20. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, et al. Continuous infusion of 5-fluorouracil and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997;80:1-7.